Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA ctDNA-positive adjuvant chemotherapy trial after curative resection of metastatic colorectal cancer
jRCT1071220087Phase 2Recruiting
- Sponsor
- Guardant Health
- Start
- Jan 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, fluorouracil, folinic acid, oxaliplatin and irinotecan in colorectal cancer (CRC) (2 arms), sponsored by Guardant Health. Primary endpoint: ctDNA negative conversion rate. Started Jan 2023; status: recruiting.
02
Drugs
bevacizumabfluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT1071220087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071220087.